RxDoctor Payments Data

Siva Gummadi, MD

Interventional Cardiology · Ocala, FLNPI 1063448488

Payments from drug & device makers

$143,177in general payments, 2019–2025

Across 609 payments — averaging $235.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$126K
  • GE HealthCare$3K
  • Angiodynamics, Inc.$2K
  • Johnson & Johnson$2K
  • Cook Medical LLC$1K
  • Boston Scientific$1K
  • plus $8K from 34 others

What the payments were for

  • Consulting fees$3,32419%
  • Food & beverage$14,59481%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$143,177 in reported general payments places this provider in the 85th percentile of 623 interventional cardiology providers in Florida.

See all interventional cardiology providers in Florida

Medicare billing

Part B allowed, 2024
$2,509,366
Medicare patients
2,010
Services billed
18,583

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban794$970,771
EntrestoSacubitril/Valsartan494$657,379
XareltoRivaroxaban244$255,104
Repatha SureclickEvolocumab163$152,313
FarxigaDapagliflozin Propanediol53$71,146
JardianceEmpagliflozin43$58,984
BrilintaTicagrelor35$40,454
MultaqDronedarone Hcl15$27,102
VerquvoVericiguat14$17,351
Praluent PenAlirocumab12$14,481
Dabigatran EtexilateDabigatran Etexilate Mesylate35$12,898
SotalolSotalol Hcl334$11,074
Metoprolol Succinate582$10,582
Ranolazine ErRanolazine81$8,816
Repatha SyringeEvolocumab15$8,606

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$1,097$970,771794 claims
NovartisEntresto$683$657,379494 claims
Johnson & JohnsonXarelto$1,712$255,104244 claims
AstraZenecaFarxiga, Brilinta$286$111,59988 claims
Boehringer IngelheimJardiance$506$58,98443 claims
Sanofi-aventis U.S. LLCMultaq$184$27,10215 claims
MerckVerquvo$424$17,35114 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 623 interventional cardiology providers in Florida.

Other interventional cardiology in Ocala

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →